HLX10 + carboplatin + pemetrexed

HLX10 + carboplatin + pemetrexed is a combination regimen under clinical investigation for the treatment of advanced or metastatic solid tumors, including lung cancer. HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody designed to block the PD-1 protein on T cells, thereby releasing immune inhibition and promoting anti-tumor immunity[1][2][4][5]. Carboplatin and pemetrexed are established small-molecule chemotherapy agents—carboplatin is a platinum-based alkylating agent causing DNA crosslinking and apoptosis, while pemetrexed is an antifolate that inhibits various enzymes involved in purine and pyrimidine synthesis, impairing DNA replication in cancer cells. This regimen harnesses the immunomodulatory effect of HLX10 in synergy with cytotoxic chemotherapy, aiming to improve outcomes in solid tumors[1][4].